Leerink Raises Merck & Co. Inc. (MRK) Price Target, Sees Upside from Cancer Drug

Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio.

Leerink Raises Merck & Co. Inc. (MRK) Price Target, Sees Upside from Cancer Drug

Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On March 2, Leerink Partners boosted its price target for Merck & Co. Inc. (NYSE:MRK) to $129 from $128, with an Outperform rating, highlighting potential upside for the company’s cancer medicine belzutifan. The firm stated that belzutifan has been an underrated growth engine for Merck.

In fiscal year 2025, Merck & Co. Inc. (NYSE:MRK) recorded $603 million in sales of monotherapy belzutifan for late-line treatment in the US, with a further $113 million in sales outside the country. The drug’s highest sales are estimated by consensus to be around $2.6 billion, with about $1.6 billion coming from the US.

According to Leerink, belzutifan-based regimens showed promising results in the Phase 3 LITESPARK-011 and LITESPARK-022 studies for adjuvant clear cell renal cell carcinoma and post-PD(L)1. The firm anticipates that the second-line belzutifan plus lenvatinib pair will be widely utilized by the FDA PDUFA time frame in October 2026.

Merck & Co. Inc. (NYSE:MRK) is a healthcare company that offers human health pharmaceuticals, veterinary pharmaceuticals, vaccines & health management solutions and services.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.